Novo Nordisk A/S (NONOF)
Novo Nordisk A/S (NONOF) Stock Price, Analysis & Data
| Precio de compra | 44.65 |
| Capitalización de mercado | 204.74B |
| Ingresos (TTM) | 329.43B |
| Beneficio neto (TTM) | 116.44B |
| Beta | 0.35 |
| EPS (TTM) | 4.07 |
| Ratio PER (TTM) | 11.38 |
| Adelante PE | n/a |
| P/B (TTM) | 5.98 |
| P/S (TTM) | 0.62 |
| Earnings Date | Nov 4, 2026 |
| Precio de venta | 47.66 |
| Volumen | 1,000 |
| Volumen medio (20D) | 40,390 |
| Abierto | 44.78 |
| Anterior Cerrar | 44.92 |
| Rango del día | 44.78 - 44.78 |
| Rango de 52 semanas | 34.00 - 64.75 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | $1.8 (3.96%) |
| Fecha ex dividendo | 14 ago 2026 |
Acerca de NONOF
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine...
Desempeño financiero
En 2025, los ingresos de Novo Nordisk A/S fueron 309.06B, un aumento de 6.43% en comparación con 290.4B del año anterior. Las ganancias fueron 102.43B, un aumento de 1.43%.
Estados financierosLos analistas proyectan ingresos de ... Actualizar
18 horas hace · Simply Wall St.
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Undervalued After Dutch Court WinNovo Nordisk stock has fallen sharply over the past three years, yet the broader valuation checks still flag it as looking cheap rather than stretched. Recent headlines around obesity treatments, inte...
